CSIMarket


Immunic Inc   (IMUX)
Other Ticker:  
 


 

Immunic Inc

IMUX's Financial Statements and Analysis



Immunic Inc narrowed first quarter of 2024 net loss per share of $-0.30 compare to net loss per share of $-0.58 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.37 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.3 $  0 Mill
$+0.28     Unch.    



Immunic Inc 's Revenue fell by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by sequentially.


Immunic Inc is

More on IMUX's Income Statement



Immunic Inc in the first quarter of 2024 recorded net loss of $-29.584 million, an increase from net loss of $-25.272 million in I. Quarter a year ago.

Sequentially net loss advanced

More on IMUX's Growth

Immunic Inc Inventories
IMUX's Cash flow In the first quarter of 2024 company's net cash flow was $51 million, capital expenditures grew by -0.104-70.19%, to $0 millions compare to same quarter a year ago

More on IMUX's Cash flow Statement


Immunic Inc does not pay out common stock dividend.

In trailing twelve-month period Immunic Inc payed $ -0.77 cash per share, on a free-cash flow basis .

Book value grew by 31.72 % sequentially to $0.86 per share.
Tangible Book value grew to $ 0.86 per share from $ 0.65.

Company issued 52.93 million shares or 119.31 % in Mar 31 2024.


More on IMUX's Dividends

 Market Capitalization (Millions) 126
 Shares Outstanding (Millions) 97
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -98
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Immunic Inc does not pay out common stock dividend.

In trailing twelve-month period Immunic Inc had negative $ -0.77 cash flow per share, on a free-cash flow basis .

Book value grew by 31.72 % sequentially to $0.86 per share.
Tangible Book value grew to $ 0.86 per share from $ 0.65.

Company issued 52.93 million shares or 119.31 % in Mar 31 2024.


More on IMUX's Balance Sheets

 Market Capitalization (Millions) 126
 Shares Outstanding (Millions) 97
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -98
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Immunic Inc Earnings

IMUX Shares Surge as First Quarter 2024 Results Exceed Expectations

The recent earnings report from Immunic Inc has raised eyebrows amo...

IMUX Reveals Impressive Financial Progress in Fourth Quarter of 2023

In the ongoing earnings cycle for the fiscal period of October to December 31, 2023, several companies in the Major Pharmaceutical Preparations sector have reported their financial results. One of these companies, IMUX, recently disclosed an operating deficit of $-23.381 million for the fiscal interval ending December 31, 2023. This represents a significant improvement compared to the operating deficit of $-57.327 million reported in the fourth quarter of 2022.
The reduction in operating deficit shows positive signs for IMUX as the company continues to refine its business model and strive for financial sustainability. Additionally, there has been a notable decrease in net loss, with losses decreasing fro...

Immunic Inc's Third Quarter Performance Dismays Investors with $-23.57 Million Loss

/>The Major Pharmaceutical Preparations sector is closely analyzing the financial results of Immunic Inc. for the third quarter of 2023. The company, known as IMUX in the market, recently reported an operating loss of $-23.57 million for the July to September quarter. Despite the absence of any mention of top-line figures, investors anticipate the emergence of new revenue sources in the near future. However, the IMUX's recent organizational and operational excellence has not instilled confidence among investors. The third quarter of 2023 earnings season has magnified the challenges faced by the company, with shortfalls reaching $-22.769 million. Immunic Inc is expected to release its next financial report on...

Immunic Inc Experiences Escalation in Operational Expenditure Amid Second Quarter of 2023, Mirroring Trends in Major Pharmaceutical Preparations Industry

Immunic Inc: A Promising Future in Pharmaceutical Preparations
In the ever-evolving realm of pharmaceutical preparations, Immunic Inc has emerged as a strong contender, demonstrating resilience and determination in the face of challenges. Despite recent negative financial figures, the company's stock has shown remarkable growth. With the markets eagerly anticipating new revenue sources, Immunic Inc is well-positioned to capitalize on the bullish sentiments surrounding the Major Pharmaceutical Preparations industry.
The second quarter of 2023 proved to be a testing period for Immunic Inc, as the company reported a net loss of $-23.999 million. While this may raise concerns for some investors, it is es...

Struggling Immunic Inc Reveals Challenging First Quarter Results, Casting Doubt on Future Returns

Investors and stakeholders in the stock market must approach Immunic Inc with caution due to its recording of a cumulative net loss of $-125 million in the 12 months ending in the first quarter of 2023, resulting in a negative ROI of -113.12%. With 575 other companies in the healthcare sector recording higher ROIs, Immunic Inc's poor performance is apparent. While the company's overall ROI ranking has progressed from 4595 in the fourth quarter of 2022 to 3095 in the Mar 31, 2023 quarter, this should not be relied upon as the entity is still struggling to generate positive returns.
According to the company's first-quarter earni...


Date modified: 2024-05-10T02:05:30+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com